In CLL, therapeutic activation of NK cell-mediated ADCC is induced by various humanized mAbs that target different CLL surface antigens, including CD20, CD19 and CD37 (Figure 3A, left). Here, CD37 is linked to B-cell chronic lymphocytic leukemia.